분자 감염증 검사 시장 : 제품 및 서비스별(키트, 기기), 유형별(싱글플렉스, 멀티플렉스), 검사 유형별(실험실, PoC), 질환별(성병, 인플루엔자, 위장질환, 원내감염), 기술별(PCR, NGS), 최종사용자별(진단 실험실, 병원) - 세계 예측(-2031년)

The market for molecular infectious disease testing is expected to grow from USD 11.30 billion in 2026 to reach USD 19.09 billion by 2031, at a growth rate of 11.1%.

The rapid advancement of molecular diagnostic techniques is a key driver of this market's growth. Innovations such as PCR and next-generation sequencing enhance the accuracy, speed, and efficiency of tests, making them more affordable and widely accessible.

Furthermore, companies in the market are continuously developing advanced automated diagnostic systems. This leads to more precise and rapid detection of infectious diseases, resulting in improved patient outcomes and better monitoring of emerging pathogens. Consequently, healthcare providers can make more informed decisions regarding the application of molecular diagnostics for infectious diseases.

"The laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period."

The market for molecular infectious disease testing can be divided into two main categories: laboratory tests and point-of-care tests, depending on the type of test. The laboratory tests segment is the fastest-growing due to its high accuracy and efficiency, as these tests can detect a wide range of pathogens. Laboratory tests, including PCR testing and sequencing-based testing, are particularly popular among hospitals and diagnostic laboratories because they provide precise disease identification. Significant advances in lab automation and high-throughput systems have enabled these tests to be performed efficiently. Additionally, there is a growing demand for comprehensive diagnostic tests that can detect multiple infections in a single test, further enhancing the preference for laboratory testing. With their reliable results and high diagnostic capabilities, laboratory tests offer an effective solution for detecting infectious diseases.

"The multiplex testing segment accounted for the largest market share, by type, in 2025."

The global market for molecular infectious disease testing can be divided into two main segments: singleplex testing and multiplex testing. Among these, multiplex testing leads the market due to its ability to run multiple tests simultaneously, enabling the detection and differentiation of various pathogens in a single test. This capability not only saves time, money, and effort but also makes it the preferred choice for healthcare providers. Additionally, the rise in co-infections, the need for comprehensive diagnostic tests, and the demand for accurate results in shorter timeframes have all contributed to the growth of the multiplex testing market.

"The Asia Pacific is the fastest-growing market for molecular infectious disease testing during the forecast period."

The global market for molecular infectious disease testing is segmented into the following regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries. The market is experiencing significant growth, particularly in the Asia Pacific region, driven by the high prevalence of infectious diseases in densely populated areas. There is a growing emphasis on early disease detection, which increases the demand for advanced diagnostic tools. Government and healthcare organizations are making substantial investments to enhance healthcare infrastructure, improve diagnostic facilities, and support research initiatives. Additionally, a focus on disease surveillance, outbreak management, and increased healthcare expenditure further contributes to the Asia Pacific region's significant role in the overall growth of the molecular infectious disease testing market.

The breakdown of the profile of primary participants in the molecular infectious disease testing market is:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
• By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the molecular infectious disease testing market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).

Research Coverage:

This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point-of-care tests), by disease [respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector-borne diseases, hospital-acquired infections, and other infectious diseases], by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the molecular infectious disease testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. This report covers the competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem.

Reasons to buy this report:

The report will provide market leaders and newcomers with valuable insights into the revenue figures for the overall molecular infectious disease testing market and its subsegments. It will help stakeholders comprehend the competitive landscape, enabling them to better position their businesses and formulate effective go-to-market strategies. Additionally, the report will offer insights into the current market dynamics, highlighting key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (growing global infectious disease burden, advancements in molecular diagnostic technologies, growing funding for molecular testing, and growing awareness of early disease detection), restraints (lack of standardized reimbursement structures and high cost of instruments and consumables), opportunities (expansion potential across emerging economies, rising demand for point-of-care (POC) testing), and challenges (stringent and varying regulatory requirements, operational barriers and labor shortage challenges, and supply chain disruptions for reagents and kits) influencing the growth of the molecular infectious disease testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the molecular infectious disease testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Hologic, Inc. (US), and Abbott (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW
• 3.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
• 3.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2026 VS. 2031
• 3.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2026 VS. 2031
• 3.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2026 VS. 2031
• 3.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031
• 3.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2026 VS. 2031
• 3.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing global infectious disease burden
    • 4.2.1.2 Advancements in molecular diagnostic technologies
    • 4.2.1.3 Growing funding for molecular testing
    • 4.2.1.4 Growing awareness of early disease detection
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Lack of standardized reimbursement structures
    • 4.2.2.2 High cost of instruments and consumables
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion potential across emerging economies
    • 4.2.3.2 Rising demand for point-of-care (POC) testing
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Stringent and varying regulatory requirements
    • 4.2.4.2 Operational barriers and labor shortage challenges
    • 4.2.4.3 Supply chain disruptions for reagents and kits
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
  • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024-2026
  • 5.6.2 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024-2026
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
  • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 IMPACT OF 2025 US TARIFFS ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON REGIONS
    • 5.11.4.1 North America
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES
    • 5.11.5.1 Diagnostic laboratories
    • 5.11.5.2 Hospitals & clinics
    • 5.11.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 NEXT-GENERATION SEQUENCING
  • 6.1.2 POLYMERASE CHAIN REACTION
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS
  • 6.2.2 LABORATORY INFORMATION SYSTEMS (LIS) & DIGITAL HEALTH INTEGRATION
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 CRISPR-BASED DIAGNOSTICS
  • 6.3.2 DIGITAL PCR (DPCR)
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 LIST OF MAJOR PATENTS
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GENERATIVE AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 TOP USE CASES & MARKET POTENTIAL
  • 6.7.3 KEY COMPANIES IMPLEMENTING AI
  • 6.7.4 FUTURE OF AI

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY ANALYSIS
    • 7.1.1.1 North America
      • 7.1.1.1.1 US
      • 7.1.1.1.2 Canada
    • 7.1.1.2 Europe
      • 7.1.1.2.1 Germany
      • 7.1.1.2.2 UK
      • 7.1.1.2.3 France
      • 7.1.1.2.4 Italy
    • 7.1.1.3 Asia Pacific
      • 7.1.1.3.1 China
      • 7.1.1.3.2 Japan
      • 7.1.1.3.3 India
      • 7.1.1.3.4 Australia
    • 7.1.1.4 Latin America
      • 7.1.1.4.1 Brazil
      • 7.1.1.4.2 Mexico
    • 7.1.1.5 Middle East
      • 7.1.1.5.1 Africa
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
    • 7.2.1.1 Eco-friendly initiatives
  • 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE

• 9.1 INTRODUCTION
• 9.2 REAGENTS & KITS
  • 9.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH
• 9.3 INSTRUMENTS
  • 9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH
• 9.4 SOFTWARE & SERVICES
  • 9.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 MULTIPLEX TESTING
  • 10.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH
• 10.3 SINGLEPLEX TESTING
  • 10.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH

11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE

• 11.1 INTRODUCTION
• 11.2 LABORATORY TESTS
  • 11.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH
• 11.3 POINT-OF-CARE TESTS
  • 11.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET

12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE

• 12.1 INTRODUCTION
• 12.2 RESPIRATORY INFECTIOUS DISEASES
  • 12.2.1 INFLUENZA
    • 12.2.1.1 Growing focus on faster diagnosis and control to propel market
  • 12.2.2 TUBERCULOSIS
    • 12.2.2.1 Rise in undiagnosed and untreated cases to promote growth
  • 12.2.3 PHARYNGITIS
    • 12.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth
  • 12.2.4 NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS
    • 12.2.4.1 Increasing reliance on advanced molecular diagnostic technologies to fuel growth
  • 12.2.5 OTHER RESPIRATORY INFECTIOUS DISEASES
• 12.3 GASTROINTESTINAL INFECTIOUS DISEASES
  • 12.3.1 HEPATITIS
    • 12.3.1.1 Rising global incidence of infections to expedite growth
  • 12.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES
• 12.4 SEXUALLY TRANSMITTED DISEASES
  • 12.4.1 HUMAN IMMUNODEFICIENCY VIRUS
    • 12.4.1.1 Increasing number of blood transfusions and blood donations to augment growth
  • 12.4.2 HUMAN PAPILLOMAVIRUS
    • 12.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market
  • 12.4.3 CHLAMYDIA TRACHOMATIS
    • 12.4.3.1 Increasing incidence of chlamydia to aid growth
  • 12.4.4 NEISSERIA GONORRHOEAE
    • 12.4.4.1 Increasing development of novel assays to boost market
  • 12.4.5 SYPHILIS
    • 12.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
  • 12.4.6 OTHER SEXUALLY TRANSMITTED DISEASES
• 12.5 HOSPITAL-ACQUIRED INFECTIONS
  • 12.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET
• 12.6 VAGINITIS
  • 12.6.1 INCREASING AWARENESS ABOUT WOMEN'S HEALTH TO BOLSTER GROWTH
• 12.7 MENINGITIS
  • 12.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH
• 12.8 VECTOR-BORNE DISEASES
  • 12.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET
• 12.9 BLOODSTREAM INFECTIONS & SEPSIS
  • 12.9.1 HIGH BURDEN OF BLOODSTREAM INFECTIONS TO PROPEL MARKET
• 12.10 OTHER INFECTIOUS DISEASES

13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY

• 13.1 INTRODUCTION
• 13.2 POLYMERASE CHAIN REACTION
  • 13.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
• 13.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
  • 13.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH
• 13.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
  • 13.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
• 13.5 IN SITU HYBRIDIZATION
  • 13.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET
• 13.6 DNA MICROARRAYS
  • 13.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH
• 13.7 OTHER TECHNOLOGIES

14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 DIAGNOSTIC LABORATORIES
  • 14.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
• 14.3 HOSPITALS & CLINICS
  • 14.3.1 RISING PATIENT VOLUMES TO CONTRIBUTE TO GROWTH
• 14.4 OTHER END USERS

15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 US
    • 15.2.1.1 Presence of advanced healthcare infrastructure to augment growth
  • 15.2.2 CANADA
    • 15.2.2.1 Favorable government initiatives to fuel market
• 15.3 EUROPE
  • 15.3.1 GERMANY
    • 15.3.1.1 Increasing healthcare expenditure to advance growth
  • 15.3.2 UK
    • 15.3.2.1 Growing number of diagnostic centers to fuel market
  • 15.3.3 FRANCE
    • 15.3.3.1 Increasing demand for early disease diagnosis to augment growth
  • 15.3.4 ITALY
    • 15.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market
  • 15.3.5 RUSSIA
    • 15.3.5.1 Increasing access to quality healthcare to facilitate growth
  • 15.3.6 SPAIN
    • 15.3.6.1 Growing public health initiatives to boost market
  • 15.3.7 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 CHINA
    • 15.4.1.1 Rising public access to modern healthcare to spur growth
  • 15.4.2 JAPAN
    • 15.4.2.1 Universal healthcare reimbursement policy to foster growth
  • 15.4.3 INDIA
    • 15.4.3.1 Increased private and public investments to bolster growth
  • 15.4.4 AUSTRALIA
    • 15.4.4.1 Growing investments for testing centers and treatment facilities to drive market
  • 15.4.5 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 BRAZIL
    • 15.5.1.1 Growing focus on improving healthcare infrastructure to fuel market
  • 15.5.2 MEXICO
    • 15.5.2.1 Increasing accessibility and affordability of healthcare services to foster growth
  • 15.5.3 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST & AFRICA
  • 15.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
• 15.7 GCC COUNTRIES
  • 15.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
• 16.3 REVENUE ANALYSIS, 2023-2025
• 16.4 MARKET SHARE ANALYSIS, 2025
  • 16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 16.4.2 US MARKET SHARE ANALYSIS, 2025
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Product & service footprint
    • 16.5.5.4 Disease footprint
    • 16.5.5.5 Test type footprint
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.6.5.1 Detailed list of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 16.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
  • 16.7.1 FINANCIAL METRICS
  • 16.7.2 COMPANY VALUATION
• 16.8 BRAND/PRODUCT COMPARISON
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES & APPROVALS
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 DANAHER
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product approvals
      • 17.1.1.3.2 Deals
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses & competitive threats
  • 17.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches & approvals
      • 17.1.2.3.2 Deals
      • 17.1.2.3.3 Expansions
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses & competitive threats
  • 17.1.3 BIOMERIEUX
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product launches & approvals
      • 17.1.3.3.2 Deals
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses & competitive threats
  • 17.1.4 HOLOGIC, INC.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Product approvals
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses & competitive threats
  • 17.1.5 ABBOTT
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Product approvals
      • 17.1.5.3.2 Deals
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Key strengths
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses & competitive threats
  • 17.1.6 THERMO FISHER SCIENTIFIC INC.
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Product launches
      • 17.1.6.3.2 Deals
  • 17.1.7 QIAGEN
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches & approvals
      • 17.1.7.3.2 Deals
      • 17.1.7.3.3 Expansions
  • 17.1.8 REVVITY
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products offered
  • 17.1.9 GRIFOLS, S.A.
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product approvals
  • 17.1.10 SEEGENE INC.
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Product approvals
      • 17.1.10.3.2 Deals
  • 17.1.11 DIASORIN S.P.A.
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products offered
    • 17.1.11.3 Recent developments
      • 17.1.11.3.1 Product approvals
      • 17.1.11.3.2 Deals
  • 17.1.12 SIEMENS HEALTHINEERS AG
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products offered
    • 17.1.12.3 Recent developments
      • 17.1.12.3.1 Deals
      • 17.1.12.3.2 Expansions
  • 17.1.13 BECTON, DICKINSON AND COMPANY (BD)
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products offered
    • 17.1.13.3 Recent developments
      • 17.1.13.3.1 Product approvals
      • 17.1.13.3.2 Deals
      • 17.1.13.3.3 Expansions
  • 17.1.14 SD BIOSENSOR
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products offered
    • 17.1.14.3 Recent developments
      • 17.1.14.3.1 Deals
• 17.2 OTHER PLAYERS
  • 17.2.1 QUIDELORTHO CORPORATION
  • 17.2.2 BRUKER
  • 17.2.3 GENETIC SIGNATURES
  • 17.2.4 CO-DIAGNOSTICS, INC.
  • 17.2.5 VELA DIAGNOSTICS
  • 17.2.6 MOLBIO DIAGNOSTICS PVT. LTD.
  • 17.2.7 SAVYON DIAGNOSTICS
  • 17.2.8 UNIOGEN OY
  • 17.2.9 GENEOMBIO TECHNOLOGIES
  • 17.2.10 ADVANCED MOLECULAR DIAGNOSTICS
  • 17.2.11 ALTONA DIAGNOSTICS GMBH
  • 17.2.12 GENEFIRST LIMITED

18 RESEARCH METHODOLOGY

• 18.1 RESEARCH DATA
• 18.2 SECONDARY DATA
  • 18.2.1 LIST OF SECONDARY SOURCES
  • 18.2.2 KEY DATA FROM SECONDARY SOURCES
  • 18.2.3 PRIMARY DATA
    • 18.2.3.1 List of primary sources
    • 18.2.3.2 Key data from primary sources
    • 18.2.3.3 Key industry insights
    • 18.2.3.4 Breakdown of primary interviews
• 18.3 MARKET SIZE ESTIMATION
  • 18.3.1 TOTAL MARKET SIZE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • 18.3.2 BOTTOM-UP APPROACH
    • 18.3.2.1 Approach 1: Revenue estimation of key players
    • 18.3.2.2 Approach 2: Study of annual reports and investor presentations
    • 18.3.2.3 Approach 3: Primary interviews
    • 18.3.2.4 Growth forecast
    • 18.3.2.5 CAGR projections
  • 18.3.3 TOP-DOWN APPROACH
• 18.4 DATA TRIANGULATION
• 18.5 RESEARCH ASSUMPTIONS
  • 18.5.1 STUDY-RELATED ASSUMPTIONS
• 18.6 STUDY ASSUMPTIONS
  • 18.6.1 PARAMETRIC ASSUMPTIONS
  • 18.6.2 GROWTH RATE ASSUMPTIONS
• 18.7 RESEARCH LIMITATIONS
• 18.8 RISK ASSESSMENT

19 APPENDIX

• 19.1 DISCUSSION GUIDE
• 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 19.3 RELATED REPORTS
• 19.4 AUTHOR DETAILS